Over 66,000 transplants have been performed in Brazil since 2005 giving them a new chance in life although many thousands more die on the organ transplant waiting list. Any increase in the length in the life-time of a transplanted organ reduces re-transplantation rates and frees up the precious gift-of-life of a potential suitable organ for those on the waiting list. iGeneTRAiN, an international consortium of over 20 transplant genetic studies encompassing over 32,000 samples, is aiming to reduce these issues. Our goals are to discovery of genetic variants that lead or contribute to rejection and other complications of transplantations, and to expand biomarkers found in urine and blood samples that may predict rejection weeks or months before patients show symptoms. We are poised to translate these discoveries into individualized patient treatments but we need your help.
Alexandre C. Pereira, MD, PhD,
Laboratory of Genetics & Molecular Cardiology, Heart Institute (InCor), University of São Paulo Medical School, São Paulo
Helio Tedesco, MD
Division of Nephrology, Hospital do Rim e Hipertensão, São Paulo
Patricia Severino PhD
Functional Genomics, Education & Research Institute. Albert Einstein Hospital, São Paulo
Vinicius Tragante PhD
Department of Cardiology, University Medical Center Utrecht, The Netherlands;
|We are using genetic data to help minimize transplant rejection and complications of rejection.||Three distinct phases will integrate deeply-characterized transplant and DNA data.||Three distinct phases will integrate deeply-characterized transplant and DNA data.||
A gift to iGeneTRAiN accelerates research to develop new ways to perform translational research in transplantation. Support for iGeneTRAiN can be provided in a variety of ways, including credit card. You can learn more by clicking here.